Zepbound, a drug that rivals Ozempic, may one day be a treatment for sleep apnea, according to results from a new study.
Eli Lilly beat earnings expectations for the first quarter and raised its outlook for the year.
Eli Lilly shares jumped in early trading Tuesday as the drugmaker reported
Sky-rocketing demand for Mounjaro and Zepbound, both chemically known as tirzepatide, has propelled the drugmaker's market value above $700 billion - surpassing both Tesla and Walmart. Lilly said its raised forecast reflects "greater clarity about the company's production expansion for the remainder of the year". In the short- to mid-term, the U.S. drugmaker expects sales growth for its weight-loss and diabetes treatments to primarily depend on how much it can produce and ship.
Metsera, a clinical-stage biotechnology startup that develops drugs for obesity and metabolic diseases, launched on Thursday with what it described as a “broad portfolio” of weight-loss treatments that it hopes to bring to market. The company, which has already acquired the U.K.-based startup, Zihipp, and formed a licensing pact with a South Korean drugmaker, D&D Pharmatech, claims that its products could eventually compete with industry leaders Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro....
Rilmenidine, a drug typically used to treat hypertension, has demonstrated remarkable effects in slowing down aging in worms.
Ever since college, Brad Jobling struggled with his weight, fluctuating between a low of 155 pounds when he was in his thirties to as high as 220. He spent a decade tracking calories on WeightWatchers, but the pounds he dropped always crept back onto his 5-foot-5-inch frame. A little over a year ago, the 58-year-old Manhattan resident went on a new weight loss drug called Wegovy. He’s lost 30 pounds, and has started eating healthier food and exercising—the habits behind many commercial diet...
Finland has seen a surge in demand for popular anti-obesity medications.
Plastic surgeons say the rapid weight loss can also cause the breasts to sag. Ozempic users have opened up about experiencing shifts in breast size. READ MORE: Can weight loss drugs cause facial aging? Experts views
A growing number of insurance carriers say they won't cover the cost of weight loss medications because it is too high. The change is forcing some patients to take desperate measures. NBC News' Erin McLaughlin reports.
(Bloomberg) -- There is no escaping Ozempic and Wegovy. The diabetes and obesity drugs are a global phenomenon. They’ve won over the rich and famous, generated billions in sales and blown open a new market for weight loss drugs, which Goldman Sachs estimates will reach $100 billion a year by 2030.Most Read from BloombergTesla Axes Supercharger Team in Blow to Broader EV MarketNYPD Arrests Over 300 Protesters in Crackdown on College CampusesFed to Signal Delay of Interest-Rate CutsThe Ozempic...
Eli Lilly (LLY) jumped early Tuesday after the pharma behemoth reported